UNSPSC 51332819: Mepazine or pecazine

This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U42703EIIO. European Medicines Agency schedules Pecazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09642MIG. Pecazine generally arises in the molecular formula C19H22N2S. The term PECAZINE is an International Non-Proprietary Name or INN. PECAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Mepazine or pecazine bears US NLM identifiers UMLS ID C0065954 and NCI Concept Code C76052. SMILES: S1C2C(N(CC3CCCN(C3)C)C3C1CCCC3)CCCC2.

UNSPSC 51332819 Mepazine or pecazine is a Commodity code that in recent state and local procurement activity covers pharmaceutical supply agreements, including naloxone distribution, generic pharmaceuticals, and specialty pharmacy benefit programs. State and local governments buy under this code through health departments, cooperative purchasing alliances, and human services commissions seeking to stock emergency medications, establish pharmaceutical benefit programs, and procure generic drugs and over-the-counter products for distribution across government facilities and community health initiatives. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The code reflects both direct pharmaceutical procurement for emergency response and community health and broader pharmacy benefit management contracting that coordinates supply through authorized wholesalers and manufacturers.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County issued an IFB (IFB60459723LAS) posted June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. Texas HHS issued a Request for Information (HHS0017013) on April 3, 2026, to gather vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued an RFP (S1070000015802) posted January 20, 2026, to establish multiple-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals due March 26, 2026, and contracts effective July 1, 2026. Vendors responding to MMCAP must maintain relationships with at least two of three designated wholesalers, certify cGMP and Drug Supply Chain Security Act compliance, and accept a 3 percent administrative fee on contract purchases.